Schedule 13G ownership disclosure

Denali Therapeutics Inc

Common Stock · CUSIP: 24823R105

Event date: 2024-12-31

Filing-level shares
2,740,102.00
Percent of class
7.2%
  • BAILLIE GIFFORD & CO

    Shares: 2,740,102.00 · Class: 7.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001088875-25-000028
Form type
SCHEDULE 13G/A
Filer
BAILLIE GIFFORD & CO
CIK
CIK 1088875
Filed
Feb 12, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub